Celgene Corporation (CELG) Receives Price Target

Celgene Corporation (CELG) : The consensus price target for Celgene Corporation (CELG) is $141.79 for the short term with a standard deviation of $12.26. The most optimist securities analyst among the 14 who monitor the stock believes that the stock can reach $162, however, the pessimist price target for the company is $120.

Celgene Corporation (CELG) : Zacks Investment Research ranks Celgene Corporation (CELG) as 3, which is a Hold recommendation. 14 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 17 research analysts is 1.35, which indicates as a Strong Buy.


Also, Equity Analysts at the Brokerage Firm, BTIG Research, upgrades their rating on the shares of Celgene Corporation (NASDAQ:CELG). BTIG Research has a Buy rating on the shares. Previously, the analysts had a Neutral rating on the shares. The rating by the firm was issued on August 4, 2016.

Celgene Corporation (NASDAQ:CELG): The stock opened at $107.04 on Thursday but the bulls could not build on the opening and the stock topped out at $107.30 for the day. The stock traded down to $105.38 during the day, due to lack of any buying support eventually closed down at $106.37 with a loss of -0.35% for the day. The stock had closed at $106.74 on the previous day. The total traded volume was 3,487,171 shares.

Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.